Douglas Adkins

678 total citations
17 papers, 242 citations indexed

About

Douglas Adkins is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Douglas Adkins has authored 17 papers receiving a total of 242 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Hematology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Douglas Adkins's work include Head and Neck Cancer Studies (4 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Neutropenia and Cancer Infections (3 papers). Douglas Adkins is often cited by papers focused on Head and Neck Cancer Studies (4 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Neutropenia and Cancer Infections (3 papers). Douglas Adkins collaborates with scholars based in United States, Australia and Portugal. Douglas Adkins's co-authors include Paul J. Petruska, Frank Dunphy, Gary Spitzer, William S. Velasquez, John F. DiPersio, H. Jean Khoury, C. Edward Bowers, Ravi Vij, W McIntyre and Lawrence T. Goodnough and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Douglas Adkins

15 papers receiving 239 citations

Peers

Countries citing papers authored by Douglas Adkins

Since Specialization

Citations

This map shows the geographic impact of Douglas Adkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Adkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Adkins more than expected).

Fields of papers citing papers by Douglas Adkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Adkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Adkins. The network helps show where Douglas Adkins may publish in the future.

Co-authorship network of co-authors of Douglas Adkins

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Adkins. A scholar is included among the top collaborators of Douglas Adkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Adkins. Douglas Adkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Patient‐Reported Swallowing Outcomes in HPV+ Oropharyngeal Cancer by Postoperative Chemoradiation Dose in MINT and E3311 2025 ·Otolaryngology ·(unknown), Sidharth V. Puram, Randal C. Paniello, Patrik Pipkorn, Paul Zolkind, R. Alex Harbison, Douglas Adkins, Peter Oppelt, Wade L. Thorstad, Hiram A. Gay, Anthony J. Apicelli, Michael J. Moravan, Rebecca D. Chernock, Mena Mansour, Jessica Ley, Ryan S. Jackson	2
2	Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC) 2024 ·International Journal of Radiation OncologyBiologyPhysics ·A. Dimitrios Colevas, (unknown), (unknown), (unknown), (unknown), Bruno Fang, Diogo Alpuim Costa, José Dinis, (unknown), (unknown), (unknown), (unknown), Michael F. Howland, (unknown), Douglas Adkins	0
3	675 Safety and tolerability of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (RM-HNSCC) 2023 ·SHILAP Revista de lepidopterología ·A. Dimitrios Colevas, (unknown), Venessa Chin, (unknown), John Park, Bruno Fang, Diogo Alpuim Costa, José Dinis, (unknown), Lanjia Lin, Yiran Zhang, (unknown), Michael F. Howland, Kelly K. Curtis, Douglas Adkins	0
4	Phase 2, randomized, double-blind trial of EC-18 versus placebo to mitigate the development and time course of oral mucositis from concomitant chemoradiation for head and neck cancer. 2022 ·Journal of Clinical Oncology ·Christina Henson, Daniel Clayburgh, (unknown), Deborah Jean Lee Wong, Mahesh Kudrimoti, Douglas Adkins, Steve P. Lee, Noah S. Kalman, Peter Oppelt, Krishna Rao, Ji Sun Park, Sookyung Oh, Koeun Kim, Sun Young Yoon, (unknown), Stephen T. Sonis	4
5	Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE-B84). 2022 ·Journal of Clinical Oncology ·Terrence L. Fisher, Elizabeth E. Evans, Crystal Mallow, (unknown), (unknown), Ernest Smith, John E. Leonard, Marya Chaney, J. Thaddeus Beck, Steven Hager, Tarek Mekhail, Nagashree Seetharamu, Megan Baumgart, Nabil F. Saba, Conor Steuer, Douglas Adkins, Barbara Burtness, Maurice Zauderer	1
6	Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC). 2019 ·Journal of Clinical Oncology ·Lillian L. Siu, Joshua Bauml, Douglas Adkins, A. Dimitrios Colevas, Cesar A. Perez, Jennifer H. Choe, Yang Zhang, Wen Shi, Willis H. Navarro, Missak Haigentz, Guilherme Rabinowits, David G. Pfister	3
7	Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study 2016 ·Journal of Biotechnology ·Mahesh Kudrimoti, (unknown), (unknown), Francis P. Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini	55
8	Safety Profile and Clinical Outcomes in a Phase I, Placebo-Controlled Study of Siplizumab in Acute Graft-Versus-Host Disease 2009 ·Transplantation ·Douglas Adkins, Voravit Ratanatharathorn, Harry Yang, Barbara White	9
9	Chimerism and clinical outcomes of 110 recipients of unrelated donor bone marrow transplants who underwent conditioning with low-dose, single-exposure total body irradiation and cyclophosphamide 2004 ·Blood ·Mark D. Girgis, (unknown), William Blum, Randy A. Brown, Hsiu-san Lin, H. Jean Khoury, Lawrence T. Goodnough, Ravi Vij, Steve Devine, (unknown), (unknown), (unknown), John F. DiPersio, Douglas Adkins	28
10	Primary amyloidosis patients with significant organ dysfunction tolerate autologous transplantation after conditioning with single-dose total body irradiation alone: a feasibility study 2003 ·Biology of Blood and Marrow Transplantation ·William Blum, H. Jean Khoury, (unknown), Ravi Vij, Lawrence T. Goodnough, Steve Devine, John F. DiPersio, Douglas Adkins	16
11	American Society for Blood and Marrow Transplantation guidelines for training 2001 ·Biology of Blood and Marrow Transplantation ·Elizabeth J. Shpall, Douglas Adkins, F R Appelbaum, Armand Keating, Charles F. LeMaistre, (unknown), (unknown)	2
12	Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer 1999 ·Journal of Clinical Oncology ·Douglas Adkins, Robert W. Brown, (unknown), Richard T. Maziarz, (unknown), César O. Freytes, Burton Needles, (unknown), Paula M. Fracasso, Timothy Pluard, (unknown), Thomas M. Ryan, Karen Hoelzer, (unknown), (unknown), (unknown), H. Jean Khoury, Ravi Vij, John F. DiPersio	29
13	Granulocyte collection efficiency and yield are enhanced by the use of a higher interface offset during apheresis of donors given granulocyte‐ colony‐stimulating factor 1998 ·Transfusion ·Douglas Adkins, Ali Saad, George J. Despotis, Marian Dynis, Lawrence T. Goodnough	20
14	Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy 1997 ·Bone Marrow Transplantation ·Gary Spitzer, Douglas Adkins, (unknown), William S. Velasquez, C. Edward Bowers, Frank Dunphy, (unknown), (unknown), W McIntyre, Paul J. Petruska	60
15	A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer. 1997 ·PubMed ·C. J. B. Ford, G Spitzer, William A. Reilly, Douglas Adkins	3
16	Design of preparative regimens for stem cell transplantation in breast cancer 1993 ·Breast Cancer Research and Treatment ·Gary Spitzer, Douglas Adkins, Frank Dunphy, Paul J. Petruska, V. Spencer, William S. Velasquez	4
17	Evaluation of CAPD prescription. 1991 ·PubMed ·Sergio R. Acchiardo, A. Kraus, (unknown), (unknown), Douglas Adkins, Linda W. Moore	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact